Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer
Work
Year: 2023
Type: article
Abstract: Pancreatic ductal adenocarcinoma (PDAC) is lethal in 88% of patients 1 , yet harbours mutation-derived T cell neoantigens that are suitable for vaccines 2,3 . Here in a phase I trial of adjuvant auto... more
Source: Nature
Institutions Memorial Sloan Kettering Cancer Center, BioNTech (Germany), Icahn School of Medicine at Mount Sinai, Weill Cornell Medicine, Cornell University
Cites: 64
Cited by: 637
Related to: 10
FWCI: 151.5
Citation percentile (by year/subfield): 99.99
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Sustainable Development Goal Good health and well-being
Open Access status: hybrid
APC paid (est): $11,690